loading page

Cardiac effects of oxytocin 2.5 U or carbetocin 100 µg after caesarean delivery: study protocol for a prospective randomized controlled multi-centre trial
  • +7
  • Maria Bekkenes,
  • Marte Jørgensen,
  • Anne Jacobsen,
  • Morten Fagerland,
  • Helene Rakstad-Larsen,
  • Ole Geir Solberg,
  • Lars Aaberge,
  • Olav Klingenberg,
  • Trude Steinsvik,
  • Leiv Arne Rosseland
Maria Bekkenes
Oslo University Hospital
Author Profile
Marte Jørgensen
Akershus University Hospital
Author Profile
Anne Jacobsen
Oslo University Hospital
Author Profile
Morten Fagerland
Oslo University Hospital
Author Profile
Helene Rakstad-Larsen
Oslo University Hospital
Author Profile
Ole Geir Solberg
Oslo Universitetssykehus
Author Profile
Lars Aaberge
Oslo University Hospital
Author Profile
Olav Klingenberg
Oslo University Hospital
Author Profile
Trude Steinsvik
Vestre Viken Hospital Trust
Author Profile
Leiv Arne Rosseland
Oslo University Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

Objective: Oxytocin may cause dose-dependent ischaemic echocardiogram changes, prolongation of QT time and release of myocardial biomarkers. We have previously demonstrated comparable vasodilatory effects of oxytocin and carbetocin and are now undertaking a Phase 4 trial to investigate whether carbetocin causes changes to myocardial markers. Design: Randomized controlled trial. Setting: Obstetrics units at Oslo University Hospital or and Akershus University Hospital, Norway. Population or sample: Planned enrolment of 240 healthy, singleton pregnant women aged 18 to 50 years, who are undergoing planned caesarean delivery Methods: Based on pilot study data, each participant will receive a 1 -minute intravenous injection of either oxytocin 2.5 U or carbetocin 100 µg during caesarean section. Main outcome measures: The primary outcome is prespecified as the change from baseline in high-sensitive troponin I plasma concentrations at 6–10 hours after study drug administration. Secondary outcomes include uterine tone grade at 2.5 and 5 minutes after study drug administration, adverse events for up to 48 hours after study drug administration, estimated blood loss within 8 hours of delivery, need for rescue treatment and direct/indirect costs. Results: Enrolment and primary analysis is expected to be completed by the end of 2021. Conclusions: Any potential cardiotoxicity difference between oxytocin and carbetocin will help inform treatment decisions for pregnant women.